Zobrazeno 1 - 10
of 44
pro vyhledávání: '"Gregory I., Vladimer"'
Autor:
Peter Valent, Attilio Orazi, Michael R. Savona, Mrinal M. Patnaik, Francesco Onida, Arjan A. van de Loosdrecht, Detlef Haase, Torsten Haferlach, Chiara Elena, Lisa Pleyer, Wolfgang Kern, Tea Pemovska, Gregory I. Vladimer, Julie Schanz, Alexandra Keller, Michael Lübbert, Thomas Lion, Karl Sotlar, Andreas Reiter, Theo De Witte, Michael Pfeilstöcker, Klaus Geissler, Eric Padron, Michael Deininger, Alberto Orfao, Hans-Peter Horny, Peter L. Greenberg, Daniel A. Arber, Luca Malcovati, John M. Bennett
Publikováno v:
Haematologica, Vol 104, Iss 10 (2019)
Chronic myelomonocytic leukemia (CMML) is a myeloid neoplasm characterized by dysplasia, abnormal production and accumulation of monocytic cells and an elevated risk of transforming into acute leukemia. Over the past two decades, our knowledge about
Externí odkaz:
https://doaj.org/article/036e94854de14eff8e12ed73d92b78b7
Autor:
Berend Snijder, Philipp B. Staber, Giulio Superti-Furga, Ingrid Simonitsch-Klupp, Ulrich Jäger, Peter Valent, Wolfgang R. Sperr, Maria-Theresa Krauth, Hermine Agis, Emir Hadzijusufovic, Tea Pemovska, Gregory I. Vladimer, Yannik Severin, Christoph Kornauth, Tim Heinemann
Supplementary Figure from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c1ad12d999bc755ead3e914259bf01aa
https://doi.org/10.1158/2643-3230.22545758
https://doi.org/10.1158/2643-3230.22545758
Autor:
Berend Snijder, Philipp B. Staber, Giulio Superti-Furga, Ingrid Simonitsch-Klupp, Ulrich Jäger, Peter Valent, Wolfgang R. Sperr, Maria-Theresa Krauth, Hermine Agis, Emir Hadzijusufovic, Tea Pemovska, Gregory I. Vladimer, Yannik Severin, Christoph Kornauth, Tim Heinemann
Supplementary Data from Deep Morphology Learning Enhances Ex Vivo Drug Profiling-Based Precision Medicine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::660c09c1d6cd0ca6020839440fc8f2b1
https://doi.org/10.1158/2643-3230.22545761.v1
https://doi.org/10.1158/2643-3230.22545761.v1
Autor:
Berend Snijder, Philipp B. Staber, Giulio Superti-Furga, Ingrid Simonitsch-Klupp, Ulrich Jäger, Peter Valent, Wolfgang R. Sperr, Maria-Theresa Krauth, Hermine Agis, Emir Hadzijusufovic, Tea Pemovska, Gregory I. Vladimer, Yannik Severin, Christoph Kornauth, Tim Heinemann
Drug testing in patient biopsy-derived cells can identify potent treatments for patients suffering from relapsed or refractory hematologic cancers. Here we investigate the use of weakly supervised deep learning on cell morphologies (DML) to complemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5428f04d7a546fbf75932fc5071ba7c0
https://doi.org/10.1158/2643-3230.c.6551027.v1
https://doi.org/10.1158/2643-3230.c.6551027.v1
Autor:
Philipp B. Staber, Berend Snijder, Giulio Superti-Furga, Ingrid Simonitsch-Klupp, Niklas Zojer, Christoph C. Zielinski, Dominik Wolf, Cora Waldstein, Stefan Vogt, Katrina Vanura, Emiel van der Kouwe, Peter Valent, Renate Thalhammer, Ismet Srndic, Wolfgang R. Sperr, Cathrin Skrabs, Christian Sillaber, Edgar Selzer, Ilse Schwarzinger, Ann-Sofie Schmolke, Ana-Iris Schiefer, Julius Salamon, Reinhard Ruckser, Robin Ristl, Markus Raderer, Gerald W. Prager, Edit Porpaczy, Alexander Pichler, Michael Panny, Leopold Öhler, Katharina Ocko, Thomas Noesslinger, Peter Neumeister, Leonhard Müllauer, Katsuhiro Miura, Olaf Merkel, Elisabeth Menschel, Marius E. Mayerhoefer, Simone Lubowitzki, Trang Le, Stefan Kubicek, Gerhard Krajnik, Nikolaus Krall, Barbara Kiesewetter, Lukas Kenner, Lukas Kazianka, Ulrich Jaeger, Georg Hopfinger, Mir Alireza Hoda, Daniel Heintel, Tim Heinemann, Alexander W. Hauswirth, Bernd Lorenz Hartmann, Marcus Hacker, Wolfgang Gstöttner, Hildegard T. Greinix, Klaus Geissler, Alexander Gaiger, Maurizio Forte, Verena Felsleitner-Hauer, Ruth Exner, Harald Esterbauer, Martin Erl, Ruth Eichner, Sandra Eder, Michael Bergmann, Günther Bayer, Gregory I. Vladimer, Tea Pemovska, Christoph Kornauth
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a9887042c05486a909c745cd96689d6c
https://doi.org/10.1158/2159-8290.c.6549464.v1
https://doi.org/10.1158/2159-8290.c.6549464.v1
Autor:
Leopold Öhler, Philipp B. Staber, Julius Salamon, Edit Porpaczy, Gerhard Krajnik, Gregory I. Vladimer, Harald Esterbauer, Ulrich Jaeger, Christian Sillaber, Gerald W. Prager, Katrina Vanura, Stefan Kubicek, Peter Valent, Michael Panny, Alexander W. Hauswirth, Edgar Selzer, Verena Felsleitner-Hauer, Emiel van der Kouwe, Nikolaus Krall, Marius E. Mayerhoefer, Bernd Lorenz Hartmann, Alexander Gaiger, Sandra Eder, Klaus Geissler, Mir Alireza Hoda, Dominik Wolf, Simone Lubowitzki, Peter Neumeister, Barbara Kiesewetter, Ruth Exner, Giulio Superti-Furga, Thomas Noesslinger, Elisabeth Menschel, Katsuhiro Miura, Wolfgang Gstöttner, Reinhard Ruckser, Ingrid Simonitsch-Klupp, Hildegard Greinix, Ana-Iris Schiefer, Ann-Sofie Schmolke, Cora Waldstein, Georg Hopfinger, Christoph C. Zielinski, Wolfgang R. Sperr, Marcus Hacker, Trang Le, Robin Ristl, Christoph Kornauth, Lukas Kazianka, Tea Pemovska, Günther Bayer, Cathrin Skrabs, Markus Raderer, Ruth Eichner, Alexander Pichler, Lukas Kenner, Maurizio Forte, Renate Thalhammer, Stefan Vogt, Leonhard Müllauer, Katharina Ocko, Niklas Zojer, Berend Snijder, Ilse Schwarzinger, Olaf Merkel, Martin Erl, Daniel Heintel, Michael Bergmann, Tim Heinemann, Ismet Srndic
Publikováno v:
Cancer Discovery, 12 (2)
Personalized medicine aims to match the right drug with the right patient by using specific features of the individual patient's tumor. However, current strategies of personalized therapy matching provide treatment opportunities for less than 10% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5ef6465faab2cb5917a550f8e3d5a11
https://doi.org/10.1158/2159-8290.cd-21-0538
https://doi.org/10.1158/2159-8290.cd-21-0538
Autor:
Noemi Meszaros, Karin Lind, Robert Sehlke, Bojan Vilagos, Nikolaus Krall, Gregory I. Vladimer, Heinz Sill
Publikováno v:
British Journal of Haematology. 200
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::846ea41b7bec43d93081a7063ed43375
https://doi.org/10.1111/bjh.18557
https://doi.org/10.1111/bjh.18557
Autor:
Tim Heinemann, Christoph Kornauth, Yannik Severin, Gregory I. Vladimer, Tea Pemovska, Emir Hadzijusufovic, Hermine Agis, Maria-Theresa Krauth, Wolfgang R. Sperr, Peter Valent, Ulrich Jäger, Ingrid Simonitsch-Klupp, Giulio Superti-Furga, Philipp B. Staber, Berend Snijder
Publikováno v:
Blood cancer discovery. 3(6)
Drug testing in patient biopsy-derived cells can identify potent treatments for patients suffering from relapsed or refractory hematologic cancers. Here we investigate the use of weakly supervised deep learning on cell morphologies (DML) to complemen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::26fa6815a69125f3c8414b337984a45c
https://pubmed.ncbi.nlm.nih.gov/36125297
https://pubmed.ncbi.nlm.nih.gov/36125297
Autor:
Tea Pemovska, Alexander Pichler, Leonhard Muellauer, Wolfgang R. Sperr, Trang Le, Ulrich Jaeger, Katrina Vanura, Christoph Kornauth, Nikolaus Krall, Giulio Superti-Furga, Renate Thalhammer, Peter Neumeister, Philipp B. Staber, Gregory I. Vladimer, Edit Porpaczy, Harald Esterbauer, Christoph C. Zielinski, Julius Salamon, Reinhard Ruckser, Katharina Ocko, Ilse Schwarzinger, Ruth Eichner, Markus Raderer, Ruth Exner, Michael Panny, Gerald W. Prager, Wolfgang Gstöttner, Verena Felsleitner-Hauer, Edgar Selzer, Lukas Kenner, Maurizio Forte, Marius E. Mayerhoefer, Ana-Iris Schiefer, Lukas Kazianka, Alexander Gaiger, Günther Bayer, Ann-Sofie Schmolke, Stefan Vogt, Cora Waldstein, Daniel Heintel, Berend Snijder, Marcus Hacker, Robin Ristl, Barbara Kiesewetter, Alexander W. Hauswirth, Mir Alireza Hoda, Katsuhiro Miura, Dominik Wolf, Ingrid Simonitsch-Klupp, Cathrin Skrabs, Emiel van der Kouwe, Simone Lubowitzki, Elisabeth Menschel, Peter Valent, Hildegard Greinix, Sandra Eder, Olaf Merkel, Leopold Öhler, Michael Bergmann, Tim Heinemann, Ismet Srndic, Thomas Noesslinger
Publikováno v:
Blood. 136:2-4
Background: Aggressive hematological malignancies in relapsed/refractory setting bear a dire prognosis with low cure rates and short survival. Matching these patients to therapies is challenged by complexity due to spatial and temporal tumor evolutio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::32a7e822d529f8a6431b5e5c93b1ebe2
https://doi.org/10.1182/blood-2020-140831
https://doi.org/10.1182/blood-2020-140831
Autor:
Anita Fischer, Giulio Superti-Furga, Thomas Pap, K Dalwigk, Bernhard Brandstetter, Birgit Niederreiter, Josef S Smolen, Günter Steiner, Hans P. Kiener, Ruth A. Byrne, Johannes Holinka, Gregory I. Vladimer, Alexander Platzer, Felix Kartnig, Florian Sevelda, Thomas Karonitsch
Publikováno v:
Laboratory Investigation. 99:648-658
Fibroblast-like synoviocytes (FLS) are major contributors to joint inflammation in rheumatoid arthritis (RA). Forkhead box O 3 (FOXO3) perturbations in immune cells are increasingly linked to RA pathogenesis. Here, we show that FOXO3 is distinctly in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f038734e9f57d958b84a2157a0ebedf
https://doi.org/10.1038/s41374-018-0184-7
https://doi.org/10.1038/s41374-018-0184-7